• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名63岁有非霍奇金淋巴瘤病史且持续感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的女性,其血清学检测呈阴性,接受了恢复期血浆治疗。

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.

作者信息

Moore Joanna L, Ganapathiraju Pavan V, Kurtz Caroline P, Wainscoat Booth

机构信息

Department of Medicine, Norwalk Hospital, Norwalk, CT, USA.

Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

出版信息

Am J Case Rep. 2020 Oct 3;21:e927812. doi: 10.12659/AJCR.927812.

DOI:10.12659/AJCR.927812
PMID:33009361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7542548/
Abstract

BACKGROUND This is a case report of an immunocompromised patient with a history of non-Hodgkin lymphoma and persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who was seronegative and successfully treated with convalescent plasma. CASE REPORT A 63-year-old woman with a past medical history of non-Hodgkin lymphoma in remission while on maintenance therapy with the anti-CD20 monoclonal antibody, obinutuzumab, tested positive for SARS-CoV-2 via nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR) testing over 12 weeks and persistently tested seronegative for immunoglobulin G (IgG) antibodies using SARS-CoV-2 IgG chemiluminescent microparticle immunoassay technology. During this time, the patient experienced waxing and waning of symptoms, which included fever, myalgia, and non-productive cough, but never acquired severe respiratory distress. She was admitted to our hospital on illness day 88, and her symptoms resolved after the administration of convalescent plasma. CONCLUSIONS As the understanding of the pathogenesis of SARS-CoV-2 continues to evolve, we can currently only speculate about the occurrence of chronic infection vs. reinfection. The protective role of antibodies and their longevity against SARS-CoV-2 remain unclear. Since humoral immunity has an integral role in SARS-CoV-2 infection, various phase 3 vaccine trials are underway. In the context of this pandemic, the present case demonstrates the challenges in our understanding of testing and treating immunocompromised patients.

摘要

背景 这是一例免疫功能低下患者的病例报告,该患者有非霍奇金淋巴瘤病史,感染了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)且持续不愈,血清学检测呈阴性,经恢复期血浆治疗后成功治愈。病例报告 一名63岁女性,既往有非霍奇金淋巴瘤病史,在接受抗CD20单克隆抗体奥妥珠单抗维持治疗期间病情缓解,通过鼻咽部逆转录聚合酶链反应(RT-PCR)检测,其SARS-CoV-2呈阳性,持续超过12周,使用SARS-CoV-2 IgG化学发光微粒子免疫分析技术检测免疫球蛋白G(IgG)抗体一直呈阴性。在此期间,患者症状反复出现,包括发热、肌痛和干咳,但从未出现严重呼吸窘迫。在发病第88天,她被收入我院,输注恢复期血浆后症状缓解。结论 随着对SARS-CoV-2发病机制的认识不断深入,目前我们只能推测是慢性感染还是再次感染。抗体对SARS-CoV-2的保护作用及其持续时间仍不清楚。由于体液免疫在SARS-CoV-2感染中起着不可或缺的作用,多项3期疫苗试验正在进行。在此次疫情背景下,本病例展示了我们在理解免疫功能低下患者的检测和治疗方面所面临的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a3/7542548/aaaa407b2076/amjcaserep-21-e927812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a3/7542548/aaaa407b2076/amjcaserep-21-e927812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a3/7542548/aaaa407b2076/amjcaserep-21-e927812-g001.jpg

相似文献

1
A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.一名63岁有非霍奇金淋巴瘤病史且持续感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的女性,其血清学检测呈阴性,接受了恢复期血浆治疗。
Am J Case Rep. 2020 Oct 3;21:e927812. doi: 10.12659/AJCR.927812.
2
Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.采用两种商业免疫分析法分析 COVID-19 恢复期血浆中的 SARS-CoV-2 IgG。
J Immunol Methods. 2020 Nov;486:112837. doi: 10.1016/j.jim.2020.112837. Epub 2020 Aug 20.
3
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验,比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效(RECOVER):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.
4
A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy.一名63岁感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的女性,她发展为重症冠状病毒病2019(COVID-19)肺炎并接受了恢复期血浆治疗。
Am J Case Rep. 2020 Sep 29;21:e927662. doi: 10.12659/AJCR.927662.
5
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.恢复期血浆治疗严重急性呼吸综合征冠状病毒 2 感染的危重症患者。
Chest. 2020 Jul;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039. Epub 2020 Mar 31.
6
Rapid Serological Assays and SARS-CoV-2 Real-Time Polymerase Chain Reaction Assays for the Detection of SARS-CoV-2: Comparative Study.用于检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的快速血清学检测和SARS-CoV-2实时聚合酶链反应检测:比较研究
J Med Internet Res. 2020 Oct 30;22(10):e19152. doi: 10.2196/19152.
7
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.评估人抗 SARS-CoV-2 恢复期血浆在 COVID-19 重症成人中的疗效和安全性:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
8
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
9
Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip.评价两种 SARS-CoV-2 快速 IgM-IgG 联合抗体检测试剂盒在指尖毛细血管全血样本中的性能。
PLoS One. 2020 Sep 17;15(9):e0237694. doi: 10.1371/journal.pone.0237694. eCollection 2020.
10
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.

引用本文的文献

1
Clinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma.新型冠状病毒肺炎合并B细胞非霍奇金淋巴瘤患者的临床特征与预后
Infect Drug Resist. 2024 Oct 17;17:4501-4510. doi: 10.2147/IDR.S477107. eCollection 2024.
2
Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy.COVID-19 患者接受抗 CD20 单克隆抗体治疗后出现持续性病毒性肺炎和高死亡率。
Eur J Clin Microbiol Infect Dis. 2024 Apr;43(4):723-734. doi: 10.1007/s10096-024-04776-0. Epub 2024 Feb 15.
3
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.

本文引用的文献

1
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.轻度新冠肺炎患者体内抗SARS-CoV-2抗体的快速衰减
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
2
SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays.两种半定量免疫分析法在急诊科、住院患者和恢复期患者中对 SARS-CoV-2 抗体的特征分析。
Clin Chim Acta. 2020 Oct;509:117-125. doi: 10.1016/j.cca.2020.06.004. Epub 2020 Jun 4.
3
Persistent SARS-CoV-2 infection and the risk for cancer.
COVID-19 恢复期血浆治疗免疫功能低下患者:系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
4
SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19.SARS-CoV-2 在长期 COVID-19 期间逃避细胞毒性 T 细胞。
Nat Commun. 2023 Jan 10;14(1):149. doi: 10.1038/s41467-022-34033-x.
5
Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review.恢复期血浆疗法对 COVID-19 合并血液系统恶性肿瘤患者的疗效:一项系统评价。
Hematol Rep. 2022 Dec 12;14(4):377-388. doi: 10.3390/hematolrep14040052.
6
Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters".患有持续性新冠病毒感染的免疫功能低下患者:“长期感染者”综述
Curr Transplant Rep. 2022;9(4):209-218. doi: 10.1007/s40472-022-00385-y. Epub 2022 Nov 12.
7
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.COVID-19 患者的恢复期血浆治疗伴体液免疫缺陷:连续 3 例病例并文献复习。
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Nov;40(9):507-516. doi: 10.1016/j.eimce.2021.01.009.
8
Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.免疫性疾病和利妥昔单抗输注对 COVID-19 感染复发的影响。
Perm J. 2021 Oct 29;26(1):123-131. doi: 10.7812/TPP/21.035.
9
Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.COVID-19 合并血液系统恶性肿瘤患者的合并症和死亡率:系统评价和荟萃分析。
J Clin Lab Anal. 2022 May;36(5):e24387. doi: 10.1002/jcla.24387. Epub 2022 Apr 6.
10
SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.免疫功能低下的新冠肺炎患者中的新冠病毒2变体:根本原因及未来方向
Transfus Clin Biol. 2022 May;29(2):161-163. doi: 10.1016/j.tracli.2021.12.006. Epub 2021 Dec 29.
持续的 SARS-CoV-2 感染与癌症风险。
Med Hypotheses. 2020 Oct;143:109882. doi: 10.1016/j.mehy.2020.109882. Epub 2020 May 28.
4
Immunocompromised patients and coronavirus disease 2019: a review and recommendations for dental health care.免疫功能低下的患者与 2019 年冠状病毒病:综述与牙科保健建议。
Braz Oral Res. 2020;34:e048. doi: 10.1590/1807-3107bor-2020.vol34.0048. Epub 2020 May 15.
5
A systematic review of asymptomatic infections with COVID-19.对 COVID-19 无症状感染的系统评价。
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16. doi: 10.1016/j.jmii.2020.05.001. Epub 2020 May 15.
6
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
7
COVID-19 and Cancer Patients.新冠病毒疾病与癌症患者。
Cancer Med J. 2020;3(1):40-48. Epub 2020 Apr 3.
8
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎(COVID-19)患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
9
Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.管理肾移植受者中的 COVID-19:对近期文献和支持皮质类固醇节约性免疫抑制的病例的回顾。
Pharmacotherapy. 2020 Jun;40(6):517-524. doi: 10.1002/phar.2410. Epub 2020 May 26.
10
Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China.中国武汉 COVID-19 患者疾病严重程度、无改善和死亡率的危险因素。
Clin Microbiol Infect. 2020 Jun;26(6):767-772. doi: 10.1016/j.cmi.2020.04.012. Epub 2020 Apr 15.